Protean BioDiagnostics Opens Trial for Women with Recurrent Breast Cancer
Protean BioDiagnostics is pleased to announce it has signed a new partnership agreement with Epic Sciences (San Diego) to coordinate a clinical trial evaluating the value of liquid biopsies for women with recurrent breast cancer. Protean will work to recruit and enroll eligible patients from both the US and Canada. Liquid biopsy is a powerful method that may enable oncologists to better monitor patients and select more effective therapies for them.
“Liquid biopsies will transform the diagnosis and management of breast cancer patients and will form the foundation for more effective precision treatments in the future”.
Dr. Anthony Magliocco
or contact info@proteanbiodx.com for more information